Real Estate, Financials, Technology May 31, 2022 05:39 PM (GMT+8)
The vaccine manufacturer GlaxoSmithKline (GSK) said on May 31 that it would spend $3.3 billion to acquire affinivax, a private biopharmaceutical company, to strengthen its vaccine production line. This is a key area that GlaxoSmithKline focuses on when it is preparing to divest its consumer sector. Last month, GlaxoSmithKline spent $1.9 billion to acquire Sierra oncology to support its cancer business.
This text is a result of machine translation.